{"id":"atorvastatin-40mg-qd","safety":{"commonSideEffects":[{"rate":"1-3","effect":"Muscle pain or myalgia"},{"rate":"1-3","effect":"Elevated liver enzymes (ALT/AST)"},{"rate":"1-2","effect":"Headache"},{"rate":"<0.1","effect":"Rhabdomyolysis (rare)"},{"rate":"1-2","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL1487","moleculeType":"Small molecule","molecularWeight":"558.65"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Atorvastatin competitively binds to HMG-CoA reductase and blocks the conversion of HMG-CoA to mevalonate, a critical early step in cholesterol biosynthesis. This leads to decreased hepatic cholesterol production, upregulation of LDL receptors on hepatocytes, and enhanced clearance of LDL cholesterol from the bloodstream. The net result is significant reduction in serum LDL cholesterol and triglycerides, with modest increases in HDL cholesterol.","oneSentence":"Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:02:54.112Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia and dyslipidemia"},{"name":"Primary and secondary prevention of cardiovascular disease"},{"name":"Reduction of risk of myocardial infarction and stroke"}]},"trialDetails":[{"nctId":"NCT05488067","phase":"PHASE4","title":"Atorvastatin Therapy on Xanthoma in Alagille Syndrome","status":"COMPLETED","sponsor":"Children's Hospital of Fudan University","startDate":"2022-03-22","conditions":"Alagille Syndrome, Atorvastatin, Xanthoma","enrollment":15},{"nctId":"NCT06157099","phase":"PHASE2","title":"Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"OHSU Knight Cancer Institute","startDate":"2024-09-01","conditions":"Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIB Cutaneous Melanoma AJCC v8","enrollment":150},{"nctId":"NCT06308952","phase":"PHASE4","title":"Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation","status":"RECRUITING","sponsor":"Duan Chuanzhi","startDate":"2024-07-30","conditions":"Cerebrovascular Event, Stent Stenosis, Ischemic Stroke","enrollment":354},{"nctId":"NCT04767984","phase":"PHASE2","title":"Testing Atorvastatin to Lower Colon Cancer Risk in Longstanding Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2021-09-24","conditions":"Colorectal Carcinoma, Ulcerative Colitis","enrollment":42},{"nctId":"NCT04262206","phase":"PHASE4","title":"Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults","status":"RECRUITING","sponsor":"Duke University","startDate":"2020-09-01","conditions":"Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases","enrollment":20000},{"nctId":"NCT05761444","phase":"PHASE4","title":"Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2023-07-26","conditions":"Atherosclerotic Cardiovascular Disease","enrollment":137},{"nctId":"NCT06796660","phase":"EARLY_PHASE1","title":"Exploring the Impact of Nephropathy Formula No. 1 on Chronic Kidney Disease Patients","status":"NOT_YET_RECRUITING","sponsor":"Liu Zhanghong","startDate":"2025-09-01","conditions":"Renal Insufficiency, Chronic","enrollment":70},{"nctId":"NCT05796973","phase":"PHASE3","title":"Measuring Oncological Value of Exercise and Statin","status":"RECRUITING","sponsor":"Tampere University Hospital","startDate":"2023-03-31","conditions":"Prostate Cancer, Breast Cancer, Kidney Cancer","enrollment":240},{"nctId":"NCT04789057","phase":"PHASE4","title":"Atorvastatin Effect on Reduction of COPD Exacerbations","status":"RECRUITING","sponsor":"Medical University of Bialystok","startDate":"2022-02-11","conditions":"Copd, COPD Exacerbation, Smoking","enrollment":460},{"nctId":"NCT06750783","phase":"PHASE4","title":"The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes","status":"RECRUITING","sponsor":"Beijing Tsinghua Chang Gung Hospital","startDate":"2024-12-31","conditions":"Prediabetic State (IGT)","enrollment":398},{"nctId":"NCT04388501","phase":"PHASE1","title":"A Study Evaluating Drug Drug Interaction Between Milvexian and Atorvastatin in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2021-06-07","conditions":"Healthy","enrollment":23},{"nctId":"NCT03753555","phase":"PHASE4","title":"The Effect of InTensive Statin in Ischemic Stroke With inTracranial Atherosclerotic Plaques","status":"RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2018-12-01","conditions":"Stroke, Ischemic, Atherosclerosis, Cerebral","enrollment":100},{"nctId":"NCT06280976","phase":"PHASE4","title":"Aggressive Risk-Prevention Therapies for Coronary Atherosclerotic Plaque (ART-CAP)","status":"WITHDRAWN","sponsor":"University of Louisville","startDate":"2024-03-01","conditions":"Coronary Artery Disease, Atherosclerosis, Heart Attack","enrollment":""},{"nctId":"NCT06191991","phase":"PHASE1","title":"A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies)","status":"COMPLETED","sponsor":"Aligos Therapeutics","startDate":"2023-11-03","conditions":"Healthy Volunteers","enrollment":14},{"nctId":"NCT03872388","phase":"PHASE2","title":"Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response After Receiving Neoadjuvant Chemotherapy","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-09-23","conditions":"Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8","enrollment":6},{"nctId":"NCT04270370","phase":"PHASE1","title":"A Study of LY3478045 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-03-16","conditions":"Healthy","enrollment":72},{"nctId":"NCT03768427","phase":"PHASE3","title":"Ezetimibe (EZ)/Atorvastatin (Ator) (MK-0653C) vs. Ator in Chinese Hypercholesterolemic Participants (MK-0653C-439)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2019-05-27","conditions":"Hypercholesterolemia","enrollment":454},{"nctId":"NCT00276458","phase":"PHASE3","title":"To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2006-02","conditions":"Hypercholesterolemia","enrollment":196},{"nctId":"NCT03867110","phase":"PHASE3","title":"An Efficacy and Safety Study of Ezetimibe (MK-0653, SCH 58235) in Addition to Atorvastatin Compared to Placebo in Participants With Primary Hypercholesterolemia (MK-0653-013)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-03-06","conditions":"Hypercholesterolemia","enrollment":628},{"nctId":"NCT03867318","phase":"PHASE3","title":"Efficacy and Safety Study of Ezetimibe (SCH 58235, MK-0653) in Addition to Atorvastatin in Participants With Coronary Heart Disease or Multiple Cardiovascular Risk Factors (P00693/MK-0653-030)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2000-04-24","conditions":"Hypercholesterolemia","enrollment":621},{"nctId":"NCT04968509","phase":"PHASE3","title":"Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis","status":"RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2024-03-22","conditions":"Aortic Stenosis","enrollment":160},{"nctId":"NCT06112028","phase":"PHASE4","title":"Clinical Study of Tongxinluo Capsule in Preventing and Treating Restenosis After Intracranial and External Arterial Stenting","status":"NOT_YET_RECRUITING","sponsor":"Yanbin Li","startDate":"2023-10","conditions":"Stent Restenosis","enrollment":200},{"nctId":"NCT06096909","phase":"NA","title":"Early Initiation of Tafolecimab for Patients With Acute Coronary Syndromeundergoing Percutaneous Coronary Intervention in Chinese Population","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-11-01","conditions":"Acute Coronary Syndrome, Non ST Segment Elevation Acute Coronary Syndrome","enrollment":3684},{"nctId":"NCT03830164","phase":"PHASE2","title":"Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-11-20","conditions":"Male Erectile Disorder, Prostate Adenocarcinoma, Erectile Dysfunction, CTCAE","enrollment":14},{"nctId":"NCT01555632","phase":"NA","title":"Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivation Therapy","status":"WITHDRAWN","sponsor":"University of Nebraska","startDate":"2012-03","conditions":"Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer","enrollment":""},{"nctId":"NCT05976893","phase":"PHASE4","title":"Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer","status":"UNKNOWN","sponsor":"Xiang Xie","startDate":"2023-08-01","conditions":"ASCVD, Atherosclerotic Cardiovascular Disease, Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor","enrollment":620},{"nctId":"NCT02947620","phase":"PHASE3","title":"Metformin/Atorvastatin Combination Therapy in Subjects With Type II Diabetes and Dyslipidemia (Phase 3)","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2015-08","conditions":"Type II Diabetes, Dyslipidemia","enrollment":185},{"nctId":"NCT05870007","phase":"PHASE2","title":"Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease","status":"ENROLLING_BY_INVITATION","sponsor":"Taipei Medical University Shuang Ho Hospital","startDate":"2023-05","conditions":"Autosomal Dominant Polycystic Kidney Disease, Chronic Kidney Diseases","enrollment":30},{"nctId":"NCT05812404","phase":"PHASE1","title":"Phase 1 Clinical Trial to Evaluate the Effect of DWP14012 on the Pharmacokinetics of DWC202201 in Healthy Subjects","status":"UNKNOWN","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2022-10-26","conditions":"Drug Drug Interaction","enrollment":36},{"nctId":"NCT05165251","phase":"PHASE4","title":"Blood Pressure and Lipids Reduction in High Risk Elderly Patients With Isolated Systolic Hypertension","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2022-01-04","conditions":"Isolated Systolic Hypertension","enrollment":480},{"nctId":"NCT05372380","phase":"PHASE1","title":"A Study to Evaluate Drug-drug Interactions Between BR1017-1 and BR1017-2 in Healthy Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2022-05-09","conditions":"Hypertension, Hypercholesterinemia","enrollment":32},{"nctId":"NCT03951207","phase":"PHASE4","title":"Rosuvastatin/Amlodipine vs Atorvastatin/Amlodipine in Hypertension Patient With Dyslipidemia","status":"COMPLETED","sponsor":"Yuhan Corporation","startDate":"2019-05-30","conditions":"Dyslipidemias, Hypertension","enrollment":259},{"nctId":"NCT05131997","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of AD-221 and AD-221A","status":"COMPLETED","sponsor":"Addpharma Inc.","startDate":"2021-11-16","conditions":"Primary Hypercholesterolemia","enrollment":290},{"nctId":"NCT03709355","phase":"PHASE1","title":"Pharmacokinetics Study to Evaluate Drug-Drug Interactions and Safety of Elpida® in Co-Administration With Other Drugs","status":"COMPLETED","sponsor":"Viriom","startDate":"2018-11-14","conditions":"HIV-1-infection","enrollment":56},{"nctId":"NCT03692754","phase":"PHASE2, PHASE3","title":"Atorvastatin in Management of Newly Diagnosed ITP","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-11-01","conditions":"Immune Thrombocytopenia, Purpura, Thrombocytopenic","enrollment":30},{"nctId":"NCT04661709","phase":"PHASE4","title":"Efficacy and Safety of Wen Xin Granules for the Treatment of Unstable Angina Pectoris","status":"UNKNOWN","sponsor":"Guang'anmen Hospital of China Academy of Chinese Medical Sciences","startDate":"2021-03-01","conditions":"Coronary Heart Disease, Unstable Angina, Chinese Herbal Medicine","enrollment":502},{"nctId":"NCT01779687","phase":"PHASE1","title":"Pharmacokinetic Drug Interaction Study Between Raltegravir and Atorvastatin.","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2013-03","conditions":"HIV, Hypercholesterolaemia","enrollment":24},{"nctId":"NCT01341730","phase":"PHASE4","title":"The Effect of Atorvastatin and Pioglitazone on Carotid Atherosclerosis With the Use of Positron Emission Tomography-computed Tomography (PET-CT)","status":"TERMINATED","sponsor":"The Catholic University of Korea","startDate":"2011-06","conditions":"Atherosclerosis, Coronary Artery Disease","enrollment":41},{"nctId":"NCT01837069","phase":"PHASE4","title":"Risk Factor Control Before Orthopedic Surgery","status":"TERMINATED","sponsor":"NYU Langone Health","startDate":"2014-02","conditions":"Osteoarthritis, Cardiovascular Disease","enrollment":198},{"nctId":"NCT01709513","phase":"PHASE3","title":"Study of Alirocumab (REGN727/SAR236553) in Patients With Primary Hypercholesterolemia and Moderate, High, or Very High Cardiovascular (CV) Risk, Who Are Intolerant to Statins (ODYSSEY ALTERNATIVE)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-09-30","conditions":"Hypercholesterolemia","enrollment":314},{"nctId":"NCT02591836","phase":"PHASE2","title":"Efficacy and Safety of Gemcabene in Hypercholesterolemic Patients as Monotherapy or in Combination With Atorvastatin","status":"COMPLETED","sponsor":"NeuroBo Pharmaceuticals Inc.","startDate":"2003-01","conditions":"Hypercholesterolemia","enrollment":277},{"nctId":"NCT02587416","phase":"PHASE1","title":"Effect of Gemcabene on the Pharmacokinetics of Atorvastatin in Healthy Volunteers","status":"COMPLETED","sponsor":"NeuroBo Pharmaceuticals Inc.","startDate":"2002-11","conditions":"Hypercholesteremia","enrollment":20},{"nctId":"NCT03079115","phase":"PHASE4","title":"High Dose Atorvastatin for Preventing Periprocedural Ischemic Brain Damage During Carotid Artery Stenting","status":"UNKNOWN","sponsor":"Beijing Hospital","startDate":"2017-08-21","conditions":"Carotid Artery Stenosis","enrollment":130},{"nctId":"NCT00233480","phase":"PHASE4","title":"Statin Therapy in Heart Failure: Potential Mechanisms of Benefit","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2005-08","conditions":"Heart Failure, Congestive","enrollment":27},{"nctId":"NCT01686230","phase":"NA","title":"Acupuncture in Patients With Stable Angina Pectoris","status":"COMPLETED","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2012-07","conditions":"Angina, Stable","enrollment":404},{"nctId":"NCT02029118","phase":"EARLY_PHASE1","title":"Acupoint Application in Patients With Stable Angina Pectoris (AASAP)","status":"COMPLETED","sponsor":"Chengdu University of Traditional Chinese Medicine","startDate":"2012-10","conditions":"Stable Angina Pectoris","enrollment":200},{"nctId":"NCT03801733","phase":"PHASE1","title":"Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin","status":"COMPLETED","sponsor":"Akebia Therapeutics","startDate":"2018-06-17","conditions":"Drug Interaction Potentiation","enrollment":134},{"nctId":"NCT03860220","phase":"PHASE4","title":"The Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin","status":"UNKNOWN","sponsor":"Hyo-Soo Kim","startDate":"2019-03-01","conditions":"Hypertension, Dyslipidemias","enrollment":304},{"nctId":"NCT03482180","phase":"PHASE3","title":"Evaluate the Efficacy and Safety of KI1106 in Patients Whose TG Level is Not Adequately Controlled With Atorvastatin Calcium Monotherapy While LDL-C is Properly Controlled","status":"COMPLETED","sponsor":"Kuhnil Pharmaceutical Co., Ltd.","startDate":"2016-05-04","conditions":"Dyslipidemias","enrollment":215},{"nctId":"NCT02977065","phase":"PHASE2","title":"To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-03-23","conditions":"Dyslipidemias","enrollment":62},{"nctId":"NCT02171039","phase":"PHASE1","title":"Relative Bioavailability of Dabigatran and Atorvastatin in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2006-06","conditions":"Healthy","enrollment":24},{"nctId":"NCT02633956","phase":"PHASE2","title":"Combination Obeticholic Acid (OCA) and Statins for Monitoring of Lipids (CONTROL)","status":"COMPLETED","sponsor":"Intercept Pharmaceuticals","startDate":"2015-12-04","conditions":"Nonalcoholic Steatohepatitis","enrollment":84},{"nctId":"NCT03460808","phase":"PHASE1, PHASE2","title":"The Combination of Atorvastatin, Acetylcysteine and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2018-03-10","conditions":"Immune Thrombocytopenia","enrollment":200},{"nctId":"NCT02135029","phase":"PHASE3","title":"Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-06","conditions":"Hyperlipidemia","enrollment":184},{"nctId":"NCT00965185","phase":"NA","title":"Statin Therapy to Improve Atherosclerosis in HIV Patients","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-09","conditions":"Cardiovascular Disease, HIV, Atherosclerosis","enrollment":40},{"nctId":"NCT00770679","phase":"NA","title":"Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2008-06","conditions":"Diabetes","enrollment":16},{"nctId":"NCT02069821","phase":"PHASE1","title":"Pharmacokinetic Interactions Between Amlodipine Besylate/Valsartan and Atorvastatin in Healthy Male Subjects","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2014-03","conditions":"Healthy","enrollment":56},{"nctId":"NCT02608697","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of CAT-2054 in Combination With Atorvastatin in Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Catabasis Pharmaceuticals","startDate":"2015-10","conditions":"Hypercholesterolemia","enrollment":153},{"nctId":"NCT02790528","phase":"PHASE4","title":"Statin Therapy In Patients With Vasospastic Angina","status":"WITHDRAWN","sponsor":"Seung-Jung Park","startDate":"2017-07","conditions":"Angina Pectoris, Variant, Statins, HMG-CoA","enrollment":""},{"nctId":"NCT00532311","phase":"PHASE3","title":"Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia","status":"TERMINATED","sponsor":"Takeda","startDate":"2007-07","conditions":"Hypercholesterolemia","enrollment":411},{"nctId":"NCT00728910","phase":"PHASE2","title":"Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2008-06","conditions":"Dyslipidemia","enrollment":25},{"nctId":"NCT01720719","phase":"PHASE4","title":"Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease","status":"UNKNOWN","sponsor":"Xin Gao","startDate":"2013-05","conditions":"Fatty Liver, Dyslipidemias, Diabetes Mellitus","enrollment":120},{"nctId":"NCT01730040","phase":"PHASE3","title":"Study of the Efficacy and Safety of Alirocumab (REGN727/SAR236553) in Combination With Other Lipid-modifying Treatment (LMT) (ODYSSEY OPTIONS I)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-10","conditions":"Hypercholesterolemia","enrollment":355},{"nctId":"NCT00136981","phase":"PHASE3","title":"Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-12","conditions":"Hypercholesterolemia, Familial, Hyperlipidemia","enrollment":800},{"nctId":"NCT02192320","phase":"PHASE2","title":"The Clinical Study of Atorvastatin and Dexamethasone on Treatment for Chronic Subdural Hematoma in the Patients With Coagulation Disorders","status":"UNKNOWN","sponsor":"Oriental Neurosurgery Evidence-Based-Study Team","startDate":"2014-07","conditions":"Chronic Subdural Hematoma","enrollment":60},{"nctId":"NCT01635946","phase":"PHASE1","title":"Drug Interaction Study of Multiple Doses of Isavuconazole and Single Dose of Atorvastatin","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2012-08","conditions":"Pharmacokinetics of Isavuconazole, Pharmacokinetics of Atorvastatin, Healthy Volunteers","enrollment":24},{"nctId":"NCT02114099","phase":"PHASE2","title":"Trial of Atorvastatin on the Persistent Coronary Aneurysm in Children With Kawasaki Disease","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2007-06","conditions":"Kawasaki Disease, Aneurysm, Coronary","enrollment":20},{"nctId":"NCT00743925","phase":"PHASE2","title":"FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes","status":"COMPLETED","sponsor":"Anthera Pharmaceuticals","startDate":"2008-07","conditions":"Acute Coronary Syndrome","enrollment":625},{"nctId":"NCT00065806","phase":"PHASE3","title":"Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)","status":"COMPLETED","sponsor":"Laura Schanberg","startDate":"2003-09","conditions":"Lupus Erythematosus, Systemic","enrollment":221},{"nctId":"NCT01765023","phase":"PHASE1","title":"Pharmacokinetic Interactions Between Atorvastatin and Metformin in Healthy Male Subjects","status":"COMPLETED","sponsor":"HK inno.N Corporation","startDate":"2012-10","conditions":"Healthy","enrollment":80},{"nctId":"NCT00756886","phase":"NA","title":"Does Atorvastatin Prevent Post Operative Atrial Fibrillation After Pulmonary Resection: A Randomized Clinical Study","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2008-09","conditions":"Arrhythmia","enrollment":73},{"nctId":"NCT00487994","phase":"PHASE3","title":"Safety and Efficacy of Lapaquistat Acetate Taken Alone and With Atorvastatin in Subjects With Primary Dyslipidemia","status":"COMPLETED","sponsor":"Takeda","startDate":"2004-11","conditions":"Dyslipidemia","enrollment":2130},{"nctId":"NCT00251680","phase":"PHASE3","title":"Efficacy of Lapaquistat Acetate in Subjects Currently Treated With Lipid-Lowering Therapy.","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-10","conditions":"Type 2 Diabetes","enrollment":400},{"nctId":"NCT00868127","phase":"PHASE3","title":"Safety of Lapaquistat Acetate in Subjects With Hypercholesterolemia","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-12","conditions":"Hypercholesterolemia","enrollment":574},{"nctId":"NCT00249899","phase":"PHASE3","title":"Efficacy of Lapaquistat Acetate Alone or Combined With High-Dose Statin Therapy in Subjects With Hypercholesterolemia","status":"TERMINATED","sponsor":"Takeda","startDate":"2005-11","conditions":"Hypercholesterolemia","enrollment":649},{"nctId":"NCT00864643","phase":"PHASE2","title":"Efficacy and Safety of Lapaquistat Acetate Coadministered With Atorvastatin in Subjects With Hypercholesterolemia","status":"COMPLETED","sponsor":"Takeda","startDate":"2004-09","conditions":"Hypercholesterolemia","enrollment":172},{"nctId":"NCT00143676","phase":"PHASE3","title":"Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-08","conditions":"Hypercholesterolemia","enrollment":448},{"nctId":"NCT00683618","phase":"PHASE3","title":"Compare the Efficacy of Rosuvastatin to Atorvastatin in High Risk Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2008-05","conditions":"Hypercholesterolemia","enrollment":934},{"nctId":"NCT00134238","phase":"PHASE3","title":"Carotid B-mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrapib/Atorvastatin to Atorvastatin.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2003-11","conditions":"Mixed Hyperlipidemia","enrollment":755},{"nctId":"NCT00267280","phase":"PHASE3","title":"A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).","status":"TERMINATED","sponsor":"Pfizer","startDate":"2006-01","conditions":"Hyperlipidemia, Dyslipidemia, Hypercholesterolemia","enrollment":640},{"nctId":"NCT00926614","phase":"PHASE4","title":"Efficacy of Actos Lipitor Pegasys & Ribavirin in CHC GT 1 Patients Who Relapsed or Nonresponded to Peg/Riba","status":"COMPLETED","sponsor":"Brooke Army Medical Center","startDate":"2008-09","conditions":"Hepatitis c","enrollment":20},{"nctId":"NCT00134264","phase":"PHASE3","title":"A Study Examining Torcetrapib/Atorvastatin And Atorvastatin Effects On Clinical CV Events In Patients With Heart Disease","status":"TERMINATED","sponsor":"Pfizer","startDate":"2004-07","conditions":"Coronary Disease, Diabetes Mellitus","enrollment":15067},{"nctId":"NCT01518231","phase":"PHASE1","title":"Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke","status":"UNKNOWN","sponsor":"Zhejiang Hospital","startDate":"2012-01","conditions":"Stroke","enrollment":40},{"nctId":"NCT01386853","phase":"PHASE3","title":"Efficacy and Safety Study of Pitavastatin and Atorvastatin in High Risk Hypercholesterolemic Patients","status":"UNKNOWN","sponsor":"Tai Tien Pharmaceuticals Co., Ltd.","startDate":"2011-07","conditions":"Hyperlipidemia","enrollment":200},{"nctId":"NCT00681525","phase":"PHASE1","title":"A Multiple-Dose Pharmacokinetic Interaction Study Between ABT-335, Atorvastatin and Ezetimibe","status":"COMPLETED","sponsor":"Abbott","startDate":"2008-04","conditions":"Pharmacokinetics","enrollment":18},{"nctId":"NCT00770575","phase":"PHASE2","title":"Efficacy Study of Pioglitazone and Atorvastatin Combination Therapy in Treating Subjects With Elevated Risk for Cardiovascular Disease","status":"COMPLETED","sponsor":"Takeda","startDate":"2005-06","conditions":"Cardiovascular Diseases","enrollment":148},{"nctId":"NCT00309751","phase":"PHASE3","title":"Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia","status":"COMPLETED","sponsor":"Kowa Research Europe","startDate":"2005-12","conditions":"Type II Diabetes Mellitus, Dyslipidemia","enrollment":418},{"nctId":"NCT00344370","phase":"PHASE3","title":"Follow-On Study of Pitavastatin Versus Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia","status":"COMPLETED","sponsor":"Kowa Research Europe","startDate":"2006-08","conditions":"Type II Diabetes Mellitus, Dyslipidemia","enrollment":214},{"nctId":"NCT00620204","phase":"PHASE4","title":"Efficacy Study of Atorvastatin to Treat Variant Angina","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2008-01","conditions":"Angina Pectoris, Variant","enrollment":136},{"nctId":"NCT00760786","phase":"NA","title":"Effects of Intensive Lipid Lowering and Omega-3 Fatty Acid on Composition of Coronary Atherosclerotic Plaque","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2008-07","conditions":"Acute Coronary Syndrome","enrollment":60},{"nctId":"NCT00194402","phase":"PHASE4","title":"SLIM: Combined Effects of Slo-Niacin and Atorvastatin on Lipoproteins and Inflammatory Markers in Hyperlipidemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2003-08","conditions":"Dyslipidemia","enrollment":64},{"nctId":"NCT00211939","phase":"PHASE4","title":"CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients","status":"COMPLETED","sponsor":"Nabi Biopharmaceuticals","startDate":"2005-01","conditions":"Calcinosis, Arteriosclerosis, Hyperparathyroidism, Secondary","enrollment":203},{"nctId":"NCT00134173","phase":"PHASE3","title":"A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-10","conditions":"Coronary Disease, Coronary Arteriosclerosis, Hyperlipidemia","enrollment":1100},{"nctId":"NCT00267267","phase":"PHASE3","title":"A Clinical Trial Comparing Torcetrapib/Atorvastatin to Ezetimibe/Simvastatin In Subjects With A Cholesterol Disorder.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2006-01","conditions":"Hyperlipidemia, Dyslipidemia","enrollment":1784},{"nctId":"NCT00267254","phase":"PHASE3","title":"A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2006-01","conditions":"Hyperlipidemia, Dyslipidemia, Hypercholesterolemia","enrollment":640},{"nctId":"NCT00134498","phase":"PHASE3","title":"A Study Comparing The Efficacy & Safety Of Torcetrapib/Atorvastatin And Atorvastatin In Subjects With High Triglycerides","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-02","conditions":"Hypertriglyceridemia, Hyperlipoproteinemia Type IV","enrollment":160},{"nctId":"NCT00134511","phase":"PHASE3","title":"Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-03","conditions":"Hypercholesterolemia, Familial","enrollment":30},{"nctId":"NCT00134485","phase":"PHASE3","title":"Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2005-03","conditions":"Hypercholesterolemia, Familial, Hyperlipidemia","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Atorvastatin 40mg, QD","genericName":"Atorvastatin 40mg, QD","companyName":"Daewoong Pharmaceutical Co. LTD.","companyId":"daewoong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Atorvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol levels. Used for Hypercholesterolemia and dyslipidemia, Primary and secondary prevention of cardiovascular disease, Reduction of risk of myocardial infarction and stroke.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}